---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-22-000043"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:18:02.620316+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q3 2022: Adjusted Cash Receipts up 2% to $597M; raises FY 2022 guidance to $2,750-2,800M

## Summary
- Net cash from operating activities $539M (+15% YoY); Adjusted Cash Flow $441M (+26% YoY).
- Raised FY 2022 Adjusted Cash Receipts guidance to $2,750-2,800M, including $458M from Pfizer's Biohaven acquisition acceleration.
- Announced up to $3.0B YTD capital deployment, including R&D funding collaboration with Merck (MK-8189).
- Royalty receipts: Cystic fibrosis franchise $208M (+14%), Trelegy added $43M, Januvia/Janumet down 97% to $1M.
- Adjusted EBITDA $548M (+3%); operating costs 8% of Adjusted Cash Receipts.

## SEC filing metadata
- accession: 0001802768-22-000043
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/0001802768-22-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/rprx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-22-000043
- JSON: https://secwatch.observer/filing/0001802768-22-000043.json
- Plain text: https://secwatch.observer/filing/0001802768-22-000043.txt

## Key facts
- Earnings Releases
  Royalty Pharma plc updated its the third quarter of 2022 guidance (raised).
  - Period: the third quarter of 2022
  - Guidance: raised
  - Result: reported results
  source text: On November 8, 2022, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000180276822000043/0001802768-22-000043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.